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Suppressor T lymphocytes (Ts) have been noted in several animal tumor
models (1-3). Adoptive transfer of UV irradiation-induced Ts leads to early
developmentoffibrosarcomas in skin grafts thatwere exposedtosubcarcinogenic
doses of UV irradiation before grafting (1). In the P815 mastocytoma and the
Meth Afibrosarcoma models, tumor-induced Ts downregulate the concomitant
antitumor immunity (2, 3). In these two tumor models, adoptive therapy with
immune spleen cells causes regression ofestablished tumors only if Ts function
is abrogated in the tumor-bearing host. These data show that Ts can accelerate
the development offibrosarcomas (1), permit thegrowth ofimmunogenic tumors
in immunocompetent hosts, and inhibit otherwise effective antitumor therapy
(2, 3). Inhibition ofTs, therefore, may be a useful adjunct in antitumor immu-
notherapy. Ts have also been noted in the tolerance to contact allergens (4-6).
In these models it is possible to induce, transfer, and assay Ts function in 1-2
wk. This rapidity makes these models particularly suitable for the evaluation of
modulators ofTs function.
Cyclophosphamide (CY) is the most extensively studied inhibitor of Ts func-
tion. Treatment with CY 1-3 d before tolerization can prevent the generation
ofTs (7). However, treatment withCYaftersensitization can abrogate immunity
(7), and treatment during elicitation can abrogate the skin test reactivity (8). In
the adoptive immunotherapy of the Meth A fibrosarcoma, the memory T cell
function is not affected by CY, while the function ofcytolytic effector T cells is
abrogated by CY (9). These data suggestthat repeated administration ofCY may
subtract from the efficacy ofthe antitumor immunotherapy. Therefore, noncy-
totoxic inhibitors ofTs function may be more suitable as adjuncts in antitumor
immunotherapy.
We studied the effect ofpurified IFN-S and IFN-a on Ts based on the data of
Knop et al. (10). These authors showed that IFN-a/ft prepared in C-243 cells
induced with Newcastle disease virus inhibited the Ts induced by intravenous
administration ofdinitrobenzene sulfonic acid (DNBSO3) and dinitrophenylated
syngeneic lymphoid cells. Since purified murine IFN-a and IFN-,B are available,
we wished to determine ifIFN-a and IFN-# were required together, or ifeither
IFN-a or IFN-,B alone were sufficient to inhibit Ts function. When murine IFN-
a/,B is prepared from cell lines by induction with a virus, 5-15% ofthe IFN is a
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and 85-95% is #. Since most of the IFN-a/# is IFN-#, we reasoned that IFN-0
alone may be sufficient to inhibit Ts function. The effect ofpurified IFN-a and
IFN-# on the Ts-mediated tolerance generated by epicutaneous antigen overload
of dinitrofluorobenzene (DNFB) was measured. Our aim was to identify a
selective inhibitor of Ts function. We report our data regarding the inhibition
of Ts by IFN-0.
Materials and Methods
Mice.
￿
8-10-wk-old BALB/c ByJ mice were purchased from The Jackson Laboratory,
Bar Harbor, ME. Abdominal fur was clipped and the mice were rested for 1 wk before
starting an experiment. Six age- and sex-matched mice per group were used in individual
experiments.
Sensitization and Elicitation. These were accomplished as described previously (8).
Briefly, sensitization was done by applying 15 u1 of a 0.5% solution of DNFB (Sigma
Chemical Co., St. Louis, MO) in acetone and olive oil (4:1) to the shaved abdominal skin
on two consecutive days. Elicitation was done 5 d after the last skin painting. 20 JAI of a
0.35% DNFB solution in acetone and olive oil (4:1) was applied to the right earlobe. 24
h later, earlobe thickness was measured by a spring-loaded micrometer (Federal, Provi-
dence, RI). The difference between the right and the left earlobe thickness was considered
to be the extent of delayed-type hypersensitivity (DTH).
Induction of Tolerance and Transfer of Suppression.
￿
This was also done as described
previously (8). Ts-mediated tolerance was induced by skin painting of the shaved abdom-
inal skin with 150 wl of a 0.5% DNFB solution on two consecutive days. To transfer
suppression, 5 d after the last skin painting, the donors of Ts were sacrificed and 10'
spleen cells were transferred intravenously to each naive recipient mouse. 24 h later the
recipients were sensitized and skin tested as described above.
Murine IFN-a, IFN-#, and Mock IFN/Control Buffer.
￿
These were purchased from Lee
Biomolecular, San Diego, CA. The manufacturer reports that the IFNs were prepared
from L cells induced with the Newcastle disease virus and the mock IFN was prepared
from sham-induced L cells. The IFNs were purified chromatographically . Discontinuous
gel electrophoresis with 8-18% polyacrylamide gradients showed the IFN-a and IFN-0 to
have molecular masses of 27-28 kD and 35-36 kD respectively. The a and # preparation
contained <0.5% IFN of the opposite species. The IFN activity was quantitated by
measuring the protective effect against cytocidal infection of L cells with the encephalo-
myocarditis virus. The results were normalized to National Institutes of Health reference
units. The IFN-a (lot 85090) contained 1 .2 x 105 U/ml, IFN-# (lots 83059 and 83001)
contained 7.6 x 105 U/ml and 1 .8 x 106 U/ml, and the mock IFN/control buffer (lot
81016) contained <4 U/ml. On random testing of crude and purified IFN and mock
IFN/control buffer, the amount of endotoxin and LPS were 3-10 ng/ml, as determined
by the Limulus assay. The interferons and the mock IFN were diluted in Dulbecco's PBS,
and the desired amount of IFN in 0.2 ml was injected intravenously in each mouse via
the tail vein .
Statistical Analysis.
￿
The student's t test was used to compare the DTH reading among
the various groups.
Results
Effect ofIFN-a and -,Q on the Generation ofTs-mediated Tolerance.
￿
Tolerance to
DNFB was generated as described in Materials and Methods. IFN-a and IFN-,B
were injected at 50-1,000 U/mouse i.v., 3 h after the first oftwo skin paintings
done on two consecutive days. Elicitation was done 5 d later. As shown in Table
I, UN-0 at 1,000 U/mouse abrogated the generation oftolerance. IFN-a at the
same dosage had a much less pronounced effect.SAHASRABUDHE
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TABLE I
Inhibition of Ts-mediated Tolerance by IFN-0
* Six mice per group.
* Sensitization done by painting the shaved abdominal skin with 15 wl of a 0.5%
DNFB solution on days I and 2. Tolerization done by skin painting with 150 pl of
a 0.5% DNFB solution on days 1 and 2.
s IFN, at indicated doses, or buffer in 0.2 ml of D-PBS intravenously 3 h after the
first of two skin paintings.
Skin testing done by applying 20 ;d of a 0.35% DNFB solution to the right earlobe
on day 7. Increase in earlobe thickness measured on day 8, and expressed as the
mean ± SEM for each group.
' Significantly different (p < 0.05) as compared with groups 2-5, and 7-9.
** No significant difference between groups I and 6.
TABLE lI
Inhibition ofthe Transfer ofSuppression by IFN-0
All six groups were sensitized by painting with 15 pl of a 0.5% DNFB solution on
the shaved abdominal skin on two consecutivedays starting 24 h after the transfer
of spleen cells.
* Six mice per group.
* Spleen cells from mice tolerized to DNFB 5 d previously.
IFN, at indicated doses, or buffer in 0.2 ml D-PBS intravenously 3 h after the
transfer ofspleen cells.
' Skin testing done by applying 20 yl of a 0.35% DNFB solution to the right earlobe
5 d after the second of two sensitizations. Increase in earlobe thickness measured
24 h later, and expressed as mean ± SEM for each group.
' Significantly different (p < 0.05) as compared with groups 2-4.
** No significant difference between groups 1 and 5.
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Because our aim was to identify an inhibitor of Ts function, further experi-
ments were done with IFN-f.
Effect ofIFN-(3 on the Transfer of Suppression by Ts.
￿
Tolerance to DNFB was
generated in the donors of Ts as described in Materials and Methods. 5 d later,
108 spleen cells from these tolerized mice were intravenously transferred to each
naive mouse. 3 h later, IFN-,B wasinjected intravenously at 50-1,000 U/recipient
mouse. Sensitization was done over the next 2 d, and elicitation was done 5 d
after completion ofsensitization. As shown in Table II, IFN-0at 1,000 U/mouse
Group* Preparation* Treatment4 Increase in earlobe
thickness'
X 10-s mm
1 Sensitize - 21 .5 t 1 .4'
2 Tolerize - 4.1 t 0.7
3 Tolerize Buffer 3.6 t 0.9
4 Tolerize IFN-t3, 50 U 2.6 t 2.0
5 Tolerize IFN-,B, 500 U 8.4 t 0.9
6 Tolerize IFN-#, 1,000 U 19.0 f 0.7''**
7 Tolerize IFN-a, 50 U 4.8 t 1 .6
8 Tolerize IFN-a, 500 U 5.8 t 1 .1
9 Tolerize IFN-a, 1,000 U 11.2 t 0.8
Group*
108 Spleen
cells from to-
lerized mice*
Treatment; Increase in earlobe
thickness'
X 10-x mm
1 - - 26.3 t 1.2"*
2 + - 6.0 t 1.0
3 + Buffer 5.6 f 1.6
4 + IFN-fl, 50 U 7.6 t 1.6
5 + IFN-fl, 500 U 11 .2 ± 1.6
6 + IFN-fl, 1,000 U 24.8 t 1.2"**1576 SAHASRABUDHE
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TABLE III
Lack ofEffect ofIFN-0 on Sensitization and Elicitation
TABLE IV
* Six mice per group.
*IFN in 0.2 ml of D-PBS injected intravenously 3h after the first of two daily paintings
with 15#1 ofa 0.5% DNFB solution on the shaved abdominal skin.
IFN,at indicated doses, in 0.2 ml of D-PBS injected intravenously 3 hafter applying 20
pl ofa 0.35°6 DNFB solution to the right earlobe 5dafter the second sensitization.
Increase in earlobe thickness measured 24 hafter applying the skin test, andexpressed
as mean tSEM for each group. No significant differences among groups 1-5.
Effect ofIFN-0 on Established Tolerance
*Six mice per group.
x Tolerization done on days 1 and 2 by painting 150 pl of a 0.5% DNFB solution on the
shaved abdominal skin for groups 3-6.
i Sensitization doneon days 7 and8 by painting 15 kl of 0.5° .6 DNFB solution on the shaved
dorsum ofthe torso for groups 1, 3-6. Tolerization done on days 7 and8by painting 150
$iI of 0.5% DNFB solution on the shaved dorsum ofthe torso for group 2.
Skin testing done on day 13 by applying 20 ;I of a 0.3596 DNFB solution to the right
earlobe. Increase in earlobe thickness measured 24 h after applying the skin test, and
expressed as mean tSEMfor each group. No significant difference among groups 2-6.
Significantly different (p < 0.05) as compared with groups 2-6.
** IFN-fl, at indicated doses, or mock IFN/control buffer, at indicated doses, in 0.2 ml ofD-
PBSinjected intravenously in groups 3-63hafter the first of two sensitizations.
completelyabrogated the transfer ofsuppression by Ts. IFN-,6 at 500 U/mouse
abrogated the transfer ofsuppression to a lesser extent.
Effect of IFN-# on the Sensitization and Elicitation.
￿
Sensitization and elicitation
were done as described in Materials and Methods. IFN-0 was injected 1,000 and
10,000 U/mouse, i.v., either 3 h after the first oftwo sensitizations or 3 h after
elicitation. As shown in Table III, IFN-# up to 10,000 U/mouse had no adverse
effect on sensitization and elicitation.
Effect of IFN-0 on Established Tolerance.
￿
Tolerance to DNFB was generated
as described in Materials and Methods. 5 d after the second skin painting, the
mice were sensitized by skin painting with 15 Iul ofa 0.5% DNFB solution on the
shaved dorsal aspect ofthe torso, on two consecutive days. IFN-i# was injected at
1,000-10,000 U/mouse i.v. 3 h after the first sensitization. Elicitation was done
5 d after the second of two sensitizations. As shown in Table IV IFN-,B in the
doses tested had no effect on the persistence of tolerance.
Group* Days 1-2t Days 7-8s Increase in earlobe
thicknesst
X 10-s mm
1 - Sensitize 25.8 t 2.4'
2 - Tolerize 2.0 t 0.5
3 Tolerize Sensitize, buffer** 3.1 t 0.6
4 Tolerize Sensitize, IFN-0, 100 U 4.1 t 0.6
5 Tolerize Sensitize, IFN-fl, 500U 4.2 t 1 .0
6 Tolerize Sensitize, IFN-d, 1,000 U 4.2 t 0.6
Group* Treatment
sensitizationt
during Treatment
elicitationg
during Increase in ear-
lobe thicknesst
X 10-s mm
1 - 26.3 :t 1.2
2 IFN-0, 1,000 U - 24.6 :t 1.8
3 IFN-fl, 10,000 U - 28.0 t 2.4
4 IFN-,B, 1,000 U 22.8 :t 0.9
5 IFN-ft, 10,000 U 28.0 t 2.5SAHASRABUDHE
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Discussion
The regulatory andsuppressive mechanisms thatcontrol theinduction, expres-
sion, and duration of contact sensitivity to DNFB have been studied extensively
(11). Skin painting with high doses ofDNFB leads to the generation ofantigen-
specific Ts that are detectable by day 3, peak by day 5, and are no longer
detectable by day 11 (8, 11). Treatment of the host with CY before antigen
overload leads to the generation ofsensitization. Testing ofTs-inhibitory agents
in this setting, therefore, permits the demonstration of sensitization in the
recipient without having to do cell transfer experiments. It is for thisreason that
epicutaneous antigen overload with DNFB was chosen herein as the method for
inducing the Ts-mediated tolerance.
The datapresented show that IFN-ft alone at 1,000 U/mouse i.v. was sufficient
to inhibit the generation of Ts-mediated tolerance (Table I, group 6), and to
abrogate the transfer of suppression ofsensitization by Ts (Table II, group 6).
Comparable doses of IFN-a had a less pronounced inhibitory effect on the
generation oftolerance (Table 1, group 9). It is conceivable that higher doses of
IFN-a may abrogate Ts function. The data also show that a 10-fold higher dose
of IFN-# had no adverse effect on sensitization or elicitation (Table 111, groups
3 and 5). This is in contrast to CY, which can adversely affect sensitization (7)
and elicitation (8). Thus, IFN-ft seems to be a suitable agent for evaluation as an
adjunct in the immunotherapy ofestablished Ts-inducing tumors.
The mechanism of the inhibitory effect of IFN-# remains undefined. Since
IFN-# is administered in vivo, it is possible that it may be acting directly on Ts
or indirectly via its effect on the antigen-presenting cells (APCs). The latter
seems unlikely, since incubation ofspleen cells from tolerized mice with IFN-a/,B
in vitro, before transfer into naive recipients, is sufficient toabrogate the transfer
of suppression (10). The antiproliferative effect of IFN is mediated by (2',5')-
oligoadenylate (oligoA) (12). However, since it is difficult to enrich antigen-
specific Ts, it has not been possible to determine if IFN-,Q induces oligoA to a
greater extent in Ts as compared with other Tcells.
The concentration ofendotoxin and LPS, as determined by the Limulus assay
in the crude and purified IFN preparations, and in the mock IFN/control buffer
is 3-10 ng/ml. Since the mock IFN had no effect, and since IFN-a had minimal
effect on the generation ofthe Ts-mediated tolerance, it seems unlikely that the
contaminating endotoxin or LPS were responsible for the observed effects.
We have extended the observation of Knop et al. (10) in two respects. First,
IFN-# alone, as opposed to IFN-a/,B, was shown to be sufficient for inhibition of
Ts. Second, administration ofIFN-# at the time oftolerizing exposure to DNFB
was shown to lead to sensitization. Having shown that IFN-,B abrogates Ts
function without adversely affecting sensitization or elicitation with DNFB, it
would be important to test its effect on Ts function in a tumor model such as
the P815 mastocytoma or the meth A fibrosarcoma.
Summary
We have presented data showing that IFN-# at 1,000 U/mouse i.v. inhibits
the generation of Ts-mediated tolerance to dinitrofluorobenzene (DNFB) and
abrogates thetransfer ofsuppression by Ts. We have alsopresenteddata showing1578
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that IFN-(# up to 10,000 U/mouse i.v. has no adverse effect on sensitization and
elicitation. IFN-0 appears to be a suitable agent for evaluation as an adjunct in
the immunotherapy ofTs inducing tumors.
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